D. Nathan, J. Buse, M. Davidson, E. Ferrannini, R. Holman et al., Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol.32, issue.1, pp.193-203, 2009.
DOI : 10.2337/dc08-9025

D. Nathan, Some answers, more controversy, from UKPDS, The Lancet, vol.352, issue.9131, pp.832-833, 1998.
DOI : 10.1016/S0140-6736(98)22937-0

R. Ewart, The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study Commentary: UKPDS is well designed and clinically important, BMJ, vol.323, issue.7317, pp.854-858, 2001.
DOI : 10.1136/bmj.323.7317.854

J. Mccormack and T. Greenlahg, Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data, BMJ, vol.320, issue.7251, pp.1720-1723, 2000.
DOI : 10.1136/bmj.320.7251.1720

K. Schulz and D. Grimes, Blinding in randomised trials: hiding who got what, The Lancet, vol.359, issue.9307, pp.696-700, 2002.
DOI : 10.1016/S0140-6736(02)07816-9

A. Keech, R. Simes, P. Barter, J. Best, R. Scott et al., FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, vol.366, pp.1849-1861, 2005.

A. Keech, P. Mitchell, P. Summanen, O. Day, J. Davis et al., Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial, The Lancet, vol.370, issue.9600, pp.1687-1697, 2007.
DOI : 10.1016/S0140-6736(07)61607-9

R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto, Heart Protection Study Collaborative Group: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions, Lancet, vol.363, pp.757-767, 2004.

M. Pignone, M. Alberts, J. Colwell, M. Cushman, S. Inzucchi et al., Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation, Diabetes Care, vol.33, issue.6, pp.1395-1402, 2010.
DOI : 10.2337/dc10-0555

R. Boussageon, T. Bejan-angoulvant, M. Saadatian-elahi, S. Lafont, C. Bergeonneau et al., Effect of intensive glucose-lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes mellitus: a meta-analysis of randomised controlled trials, BMJ, 2011.

Y. Ohkubo, H. Kishikawa, E. Araki, T. Miyata, S. Isami et al., Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study, Diabetes Research and Clinical Practice, vol.28, issue.2, pp.103-117, 1995.
DOI : 10.1016/0168-8227(95)01064-K

C. Abraira, J. Colwell, F. Nuttall, C. Sawin, W. Henderson et al., Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes, Archives of Internal Medicine, vol.157, issue.2, pp.181-188, 1997.
DOI : 10.1001/archinte.157.2.181

C. The and . Group, Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, vol.358, pp.2560-2572, 2008.

W. Duckworth, C. Abraira, T. Moritz, D. Reda, N. Emanuele et al., Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes, Glucose control and vascular complications in veterans with type 2 diabetes, pp.129-139, 2009.
DOI : 10.1056/NEJMoa0808431

M. Shichiri, H. Kishikawa, Y. Ohkubo, and W. N. , Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients, Diabetes Care, vol.23, pp.21-29, 2000.

S. Thompson and J. Higgins, How should meta-regression analyses be undertaken and interpreted?, Statistics in Medicine, vol.315, issue.11, pp.1559-1573, 2002.
DOI : 10.1002/sim.1187

A. Sjølie, R. Klein, M. Porta, T. Orchard, J. Fuller et al., Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial, The Lancet, vol.372, issue.9647, pp.1385-1393, 2008.
DOI : 10.1016/S0140-6736(08)61411-7

M. Mauer, B. Zinman, R. Gardiner, S. Suissa, A. Sinaiko et al., Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes, New England Journal of Medicine, vol.361, issue.1, pp.40-51, 2009.
DOI : 10.1056/NEJMoa0808400

. Accord-study, . Group, . Accord-eye-study, . Group, E. Chew et al., Effects of medical therapies on retinopathy progression in type 2 diabetes, N Engl J Med Erratum N Engl J Med, vol.363, issue.364, pp.233-244190, 2010.

C. Lamanna, M. Monami, N. Marchionni, and E. Mannucci, Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials, Diabetes, Obesity and Metabolism, vol.46, issue.3, pp.221-228, 2011.
DOI : 10.1111/j.1463-1326.2010.01349.x

R. Holman, D. Matthews, and H. Neil, Follow-up of intensive glucose control in type 2 diabetes. The authors reply, N Engl J Med, vol.360, p.418, 2009.

K. Schulz, I. Chalmers, R. Hayes, and D. Altman, Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA: The Journal of the American Medical Association, vol.273, issue.5, pp.408-412, 1995.
DOI : 10.1001/jama.273.5.408

D. Moher, B. Pham, A. Jones, D. Cook, A. Jadad et al., Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet, pp.609-613, 1998.

L. Wood, M. Egger, L. Gluud, K. Schulz, P. Jüni et al., Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study, BMJ, vol.336, issue.7644, pp.601-6051465, 1982.
DOI : 10.1136/bmj.39465.451748.AD

J. Yudkin, Hyperglycaemia as a cardiovascular risk factor in diabetes, The Lancet, vol.372, issue.9643, pp.1036-1037, 2008.
DOI : 10.1016/S0140-6736(08)61440-3

E. Gale, The Hawthorne studies ? a fable for our time? QJM, pp.439-449, 2004.

K. Schulz, D. Altman, D. Moher, and C. Group, CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials, BMJ, 2010.

D. Moher, K. Schulz, and D. Altman, The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials, The Lancet, vol.357, issue.9263, pp.1191-1194, 2001.
DOI : 10.1016/S0140-6736(00)04337-3